Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Seres Therapeutics (MCRB) Profit After Tax (2016 - 2026)

Seres Therapeutics (MCRB) has disclosed Profit After Tax for 11 consecutive years, with -$15.3 million as the latest value for Q4 2025.

  • Quarterly Profit After Tax rose 1.93% to -$15.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $5.7 million through Dec 2025, up 4088.24% year-over-year, with the annual reading at $5.7 million for FY2025, 104.53% up from the prior year.
  • Profit After Tax hit -$15.3 million in Q4 2025 for Seres Therapeutics, down from $8.2 million in the prior quarter.
  • In the past five years, Profit After Tax ranged from a high of $88.8 million in Q3 2024 to a low of -$117.7 million in Q4 2023.
  • Historically, Profit After Tax has averaged -$21.7 million across 5 years, with a median of -$34.2 million in 2021.
  • Biggest five-year swings in Profit After Tax: surged 325.29% in 2021 and later plummeted 5199.73% in 2023.
  • Year by year, Profit After Tax stood at -$50.0 million in 2021, then soared by 95.56% to -$2.2 million in 2022, then tumbled by 5199.73% to -$117.7 million in 2023, then soared by 86.71% to -$15.6 million in 2024, then increased by 1.93% to -$15.3 million in 2025.
  • Business Quant data shows Profit After Tax for MCRB at -$15.3 million in Q4 2025, $8.2 million in Q3 2025, and -$19.9 million in Q2 2025.